PE20230075A1 - Anticuerpos anti-flt3 y composiciones - Google Patents
Anticuerpos anti-flt3 y composicionesInfo
- Publication number
- PE20230075A1 PE20230075A1 PE2022002250A PE2022002250A PE20230075A1 PE 20230075 A1 PE20230075 A1 PE 20230075A1 PE 2022002250 A PE2022002250 A PE 2022002250A PE 2022002250 A PE2022002250 A PE 2022002250A PE 20230075 A1 PE20230075 A1 PE 20230075A1
- Authority
- PE
- Peru
- Prior art keywords
- sequences seq
- seq
- sequences
- compositions
- flt3 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un anticuerpo anti-FLT3 o una porcion de union al antigeno suya que comprende: a) una cadena pesada (HC) que comprende las secuencias aminoacidicas de SEQ ID NO: 3 y 75, y una cadena liviana (LC) que comprende las secuencias aminoacidicas de SEQ ID NO: 4 y 76; b) una HC que comprende las secuencias SEQ ID NO: 13 y 75, y una LC que comprende las secuencias SEQ ID NO: 14 y 76; c) una HC que comprende las secuencias SEQ ID NO: 23 y 75, y una LC que comprende las secuencias SEQ ID NO: 24 y 76; d) una HC que comprende las secuencias SEQ ID NO 33 y 75, y una LC que comprende las secuencias SEQ ID NO: 34 y 76; e) una HC que comprende las secuencias SEQ ID NO: 43 y 75, y una LC que comprende las secuencias SEQ ID NO 44 y 76; f) una HC que comprende las secuencias SEQ ID NO: 53 y 75, y una LC que comprende las secuencias SEQ ID NO: 54 y 76; g) una HC que comprende las secuencias SEQ ID NO: 63 y 75, y una LC que comprende las secuencias SEQ ID NO: 64 y 76; o h) una HC que comprende las secuencias SEQ ID NO: 37 y 75, y una LC que comprende las secuencias SEQ ID NO: 74 y 76.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009578P | 2020-04-14 | 2020-04-14 | |
| PCT/EP2021/059646 WO2021209495A1 (en) | 2020-04-14 | 2021-04-14 | Anti-flt3 antibodies and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230075A1 true PE20230075A1 (es) | 2023-01-11 |
Family
ID=75530015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002250A PE20230075A1 (es) | 2020-04-14 | 2021-04-14 | Anticuerpos anti-flt3 y composiciones |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210317216A1 (es) |
| EP (1) | EP4136114A1 (es) |
| JP (1) | JP2023522630A (es) |
| KR (1) | KR20220167331A (es) |
| CN (1) | CN115715297A (es) |
| AU (1) | AU2021255884A1 (es) |
| BR (1) | BR112022020683A2 (es) |
| CA (1) | CA3180188A1 (es) |
| CL (1) | CL2022002833A1 (es) |
| CO (1) | CO2022014520A2 (es) |
| IL (1) | IL297269A (es) |
| MX (1) | MX2022012919A (es) |
| PE (1) | PE20230075A1 (es) |
| TW (1) | TW202200620A (es) |
| WO (1) | WO2021209495A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022020683A2 (pt) * | 2020-04-14 | 2022-11-29 | Servier Lab | Anticorpos e composições anti-flt3 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| CN106999585A (zh) * | 2014-09-28 | 2017-08-01 | 加利福尼亚大学董事会 | 对刺激性和非刺激性骨髓细胞的调节 |
| TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EP3559038B1 (en) * | 2016-12-21 | 2022-12-14 | The United States of America as represented by The Secretary Department of Health and Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| PE20191846A1 (es) * | 2017-06-02 | 2019-12-31 | Pfizer | Anticuerpos especificos para flt3 y sus usos |
| KR20210082444A (ko) * | 2018-09-11 | 2021-07-05 | 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 | 개선된 항-flt3 항원 결합 단백질 |
| BR112022020683A2 (pt) * | 2020-04-14 | 2022-11-29 | Servier Lab | Anticorpos e composições anti-flt3 |
-
2021
- 2021-04-14 BR BR112022020683A patent/BR112022020683A2/pt unknown
- 2021-04-14 WO PCT/EP2021/059646 patent/WO2021209495A1/en active Application Filing
- 2021-04-14 IL IL297269A patent/IL297269A/en unknown
- 2021-04-14 MX MX2022012919A patent/MX2022012919A/es unknown
- 2021-04-14 US US17/230,289 patent/US20210317216A1/en active Pending
- 2021-04-14 KR KR1020227039594A patent/KR20220167331A/ko active Search and Examination
- 2021-04-14 EP EP21718860.6A patent/EP4136114A1/en active Pending
- 2021-04-14 TW TW110113434A patent/TW202200620A/zh unknown
- 2021-04-14 JP JP2022562446A patent/JP2023522630A/ja active Pending
- 2021-04-14 CN CN202180042192.0A patent/CN115715297A/zh active Pending
- 2021-04-14 PE PE2022002250A patent/PE20230075A1/es unknown
- 2021-04-14 CA CA3180188A patent/CA3180188A1/en active Pending
- 2021-04-14 AU AU2021255884A patent/AU2021255884A1/en active Pending
-
2022
- 2022-10-13 CO CONC2022/0014520A patent/CO2022014520A2/es unknown
- 2022-10-14 CL CL2022002833A patent/CL2022002833A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021209495A1 (en) | 2021-10-21 |
| KR20220167331A (ko) | 2022-12-20 |
| CO2022014520A2 (es) | 2022-11-08 |
| AU2021255884A1 (en) | 2022-11-17 |
| IL297269A (en) | 2022-12-01 |
| MX2022012919A (es) | 2022-11-16 |
| BR112022020683A2 (pt) | 2022-11-29 |
| EP4136114A1 (en) | 2023-02-22 |
| CN115715297A (zh) | 2023-02-24 |
| CL2022002833A1 (es) | 2023-06-09 |
| CA3180188A1 (en) | 2021-10-21 |
| US20210317216A1 (en) | 2021-10-14 |
| JP2023522630A (ja) | 2023-05-31 |
| TW202200620A (zh) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2569409T3 (es) | Composiciones de anticuerpo anti-CTLA-4 | |
| ES2525477T3 (es) | Anticuerpos anti-factor D humanizados | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| ES2689746T3 (es) | Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer | |
| CO6220978A2 (es) | Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| RS54133B1 (en) | ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES | |
| CL2018001177A1 (es) | Anticuerpos vinculados especificamente a pd-1 y sus usos. | |
| CO6331346A2 (es) | Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo | |
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| PE20050727A1 (es) | Anticuerpos dirigidos a c-met | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| ES2685823T3 (es) | Anticuerpos antagonistas anti-CD40 | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| CO5720212A1 (es) | Composicion de anticuerpo her2 | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20090046A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| EA200870208A1 (ru) | Конструкт однодоменного антитела | |
| PE20211708A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 |